In this Feb. 26, 2019 file photo, Albert Bourla, chief executive officer of Pfizer, prepares to testify before the Senate Finance Committee hearing on drug prices, on Capitol Hill in Washington. Pfizer Inc.'s CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes well. The announcement on Friday, Oct. 16, 2020, by Bourla reflects estimates from leading scientists that its unlikely data would start to emerge until November or December showing any of the leading vaccine candidates work. (AP Photo/Pablo Martinez Monsivais, File)
Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday.
Despite President Donald Trump’s repeated promises of a vaccine before Election Day, scientists have been cautioning that it’s unlikely data showing a leading shot actually works would come until November or December.
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.
Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. But in Friday’s announcement, he made clear that effectiveness is only part of the equation.
The vaccine also must be proven safe. And to qualify for an “emergency use authorization,” any COVID-19 vaccine must track at least half the participants in large-scale studies for two months after their second dose, the time period in which side effects are likely to appear.
Bourla estimated Pfizer's 44,000-person study will reach that milestone in the third week of November.
“We are operating at the speed of science,” he wrote in a letter posted to the company’s website.
The vaccine made by Pfizer and its German partner BioNTech is among several leading candidates in final testing.
Even if a vaccine emerges by year’s end, only limited doses will be available right away. The U.S. government is deciding who would be first in line, almost certainly health care workers, and estimates there may be enough for widespread vaccinations in the spring.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Whether it’s a deepfake video of actor Tom Cruise discovering gum in a lollipop or President Joe Biden discouraging people from voting via telephone, you’ve likely come across a deepfake video, photo or audio recording.
Tensions in the South China Sea, Apple moving to India, and banning TikTok? The podcast ‘Face Off: The U.S. Versus China’ helps explain how we got here.
Cust2Mate is a leading innovator in retail technology, aiming to revolutionize the shopping experience. By implementing smart cart technology, the tech company addresses the issue of theft while enhancing the shopper's journey.
The Biden administration has unveiled a plan, Plan B, to address the student loan debt crisis. It offers to cancel up to $20,000 in interest for borrowers enrolled in income-driven repayment plans. This proposal aims to reset balances for those facing growing debt due to unpaid interest, benefiting low—and middle-income borrowers. An estimated 25 million borrowers are eligible for some form of interest forgiveness.
As we head into the second quarter, there’s an argument in favor of buying Boeing stock. Why? As one expert says, ‘there’s nowhere else to get planes.’
With inflation and prices still on the rise, it might be worth considering a carpool app. One of them, Singapore-based Ryde, just went public in the U.S.
Full Glass Wine Co., the company behind Bright Cellars, Wine Insiders, and Winc, knows you fell in love with home delivery during the pandemic – and it’s investing millions into making it even better.
